Citations

Clear

9383 citation(s) found for "Thomas, PS".

Serum lactate and mean arterial pressure thresholds in patients with cirrhosis and septic shock
Smith, Thomas N. , Choi, Chansong , Rattan, Puru , Serafim, Laura Piccolo, Kassmeyer, Blake A., Lennon, Ryan J. , Gajic, Ognjen , Olson, Jody C. , Kamath, Patrick S. , Moraes, Alice Gallo de , Piccolo Serafim, Laura, Simonetto, Douglas A , Choi, Chansong , Gallo de Moraes, Alice , Gajic, Ognjen , Simonetto, Douglas A.

Mayo Clinic

Hepatology Communications | January 5, 2024 | Volume: 8 | Issue: 1 | Pages: No page available

10.1097/hc9.0000000000000353 | PMID 38180993 Get It

Background: The Sepsis-3 guidelines have incorporated serum lactate levels of >2 mmol/L in septic shock definition to account for higher observed mortality. Further evidence is needed to support this threshold in cirrhosis, as well as target mean arterial pressure (MAP) during resuscitation. Methods: This observational cohort study investigated the association between initial serum lactate and resuscitation MAP levels on in-hospital mortality in patients with and without cirrhosis. Patients admitted to the intensive care unit for the treatment of septic shock between 2006 and 2021 in a quaternary academic center were included. Patients with cirrhosis documented on imaging and International Classification of Disease codes (n=595) were compared to patients without cirrhosis (n=575). The association of intensive care unit admission lactate levels and median 2-hour MAP with in-hospital mortality and the need for continuous renal replacement therapy was assessed. The association between median 24-hour MAP and in-hospital mortality was analyzed post hoc. Results: Within the cirrhosis group, admission lactate levels of 2–4 and >4 mmol/L were associated with increased in-hospital mortality compared to lactate <2 mmol/L [adjusted odds ratio (aOR): 1.69, CI: 1.03–2.81, aOR: 4.02, CI: 2.53–6.52]. Median 24-hour MAP 60–65 and <60 mm Hg were also associated with increased in-hospital mortality compared with MAP >65 mm Hg (aOR: 2.84, CI: 1.64–4.92 and aOR: 7.34, CI: 3.17–18.76). In the noncirrhosis group, associations with in-hospital mortality were weaker for lactate 2–4 and >4 mmol/L (aOR: 1.32, CI: 0.77–2.27 and aOR: 2.25, CI: 1.40–3.67) and median 24-hour MAP 60–65 and <60 mm Hg (aOR: 1.70, CI: 0.65–4.14 and aOR: 4.41, CI: 0.79–29.38). Conclusions: These findings support utilizing lactate >2 mmol/L in the definition of septic shock, as well as a target MAP of >65 mm Hg during resuscitation in patients with cirrhosis.
Motion artifact correction in cardiac CT using cross-phase temporospatial information and synergistic attention gate and spatial transformer sub-networks
Gong, Hao , Ahmed, Zaki, Chang, Shaojie , Koons, Emily K. , Thorne, Jamison E. , Foley, Thomas A. , Gong, Hao , Rajiah, Prabhakar , Fletcher, Joel G. , McCollough, Cynthia H. , Leng, Shuai

Mayo Clinic

Physics in Medicine & Biology | January 5, 2024 | Volume: 69 | Issue: 3 | Pages: 035023

10.1088/1361-6560/ad1b6a | PMID 38181426 Get It

Abstract Objectives. To improve quality of coronary CT angiography (CCTA) images using a generalizable motion-correction algorithm. Approach . A neural network with attention gate and spatial transformer (ATOM) was developed to correct coronary motion. Phantom and patient CCTA images (39 males, 32 females, age range 19–92, scan date 02/2020 to 10/2021) retrospectively collected from dual-source CT were used to create training, development, and testing sets corresponding to 140- and 75 ms temporal resolution, with 75 ms images as labels. To test generalizability, ATOM was deployed for locally adaptive motion-correction in both 140- and 75 ms patient images. Objective metrics were used to assess motion-corrupted and corrected phantom and patient images, including structural-similarity-index (SSIM), dice-similarity-coefficient (DSC), peak-signal-noise-ratio (PSNR), and normalized root-mean-square-error (NRMSE). In objective quality assessment, ATOM was compared with several baseline networks, including U-net, U-net plus attention gate, U-net plus spatial transformer, VDSR, and ResNet. Two cardiac radiologists independently interpreted motion-corrupted and -corrected images at 75 and 140 ms in a blinded fashion and ranked diagnostic image quality (worst to best: 1–4, no ties). Main results . ATOM improved quality metrics ( p < 0.05) before/after correction: in phantom, SSIM 0.87/0.95, DSC 0.85/0.93, PSNR 19.4/22.5, NRMSE 0.38/0.27; in patient images, SSIM 0.82/0.88, DSC 0.88/0.90, PSNR 30.0/32.0, NRMSE 0.16/0.12. ATOM provided more consistent improvement of objective image quality, compared to the presented baseline networks. The motion-corrected images received better ranks than un-corrected at the same temporal resolution ( p < 0.05): 140 ms images 1.65/2.25, and 75 ms images 3.1/3.2. The motion-corrected 75 ms images received the best rank in 65% of testing cases. A fair-to-good inter-reader agreement was observed (Kappa score 0.58). Significance . ATOM reduces motion artifacts, improving visualization of coronary arteries. This algorithm can be used to virtually improve temporal resolution in both single- and dual-source CT.
Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States : Recommendations from a panel of experts
Karam, Chafic , Mauermann, Michelle L. , Ajroud‐Driss, Senda , Brannagan, Thomas H., Polydefkis, Michael , Mauermann, Michelle L , Karam, Chafic , González-Duarte, Alejandra , Kaku, Michelle C.

Mayo Clinic

Muscle & Nerve | January 4, 2024 | Volume: 69 | Issue: 3 | Pages: 273-287

10.1002/mus.28026 | PMID 38174864 Get It

Abstract Hereditary transthyretin (ATTRv; v for variant) amyloidosis is a rare, multisystem, progressive, and fatal disease in which polyneuropathy is a cardinal manifestation. Due to a lack of United States (US)‐specific guidance on ATTRv amyloidosis with polyneuropathy, a panel of US‐based expert clinicians convened to address identification, monitoring, and treatment of this disease. ATTRv amyloidosis with polyneuropathy should be suspected in unexplained progressive neuropathy, especially if associated with systemic symptoms or family history. The diagnosis is confirmed through genetic testing, biopsy, or cardiac technetium‐based scintigraphy. Treatment should be initiated as soon as possible after diagnosis, with gene‐silencing therapeutics recommended as a first‐line option. Consensus is lacking on what represents “disease progression” during treatment; however, the aggressive natural history of this disease should be considered when evaluating the effectiveness of any therapy.
Adult Congenital Heart Disease in the Emergency Department
Lindor, Rachel A. , Heller, Kim, Hodgson, Nicole R. , Kishi, Patrick , Monas, Jessica , Thomas, Aaron , Urumov, Andrej , Walker, Laura , Majdalany, David , Urumov, Andrej , Walker, Laura E , Majdalany, David S , Lindor, Rachel A , Rappaport, Douglas , Thomas, Aaron

Mayo Clinic

Journal of Personalized Medicine | January 4, 2024 | Volume: 14 | Issue: 1 | Pages: 66

10.3390/jpm14010066 | PMID 38248767 Get It

While congenital heart disease historically was a pathology primarily restricted to specialized pediatric centers, advances in technology have dramatically increased the number of people living into adulthood, the number of complications faced by these patients, and the number of patients visiting non-specialized emergency departments for these concerns. Clinicians need to be aware of the issues specific to patients’ individual congenital defects but also have an understanding of how typical cardiac pathology may manifest in this special group of patients. This manuscript attempts to provide an overview of this diverse but increasingly common group of adult patients with congenital heart diseases, including a review of their anatomical variants, the complications they face at the highest rates, and ways that emergency physicians may need to manage these patients differently to avoid causing harm.
MRI Features of Pelvic Nerve Involvement in Endometriosis
Çolak, Ceylan , Chamié, Luciana Pardini , Youngner, Jonathan , Forney, Michael C. , Gubbels, Ashley , VanBuren, Wendaline M. , Feldman, Myra , Chamie, Luciana P , Luna Russo, Miguel A, Gubbels, Ashley , VanBuren, Wendaline M , Feldman, Myra , Russo, Miguel Luna

Mayo Clinic

RadioGraphics | January 3, 2024 | Volume: 44 | Issue: 1 | Pages: No page available

10.1148/rg.230106 | PMID 38170677 Get It

O0010 EFFECT OF MATERNAL DOCOSAHEXAENOIC ACID (DHA) SUPPLEMENTATION ON NEUROPSYCHOLOGICAL AND VISUAL STATUS OF FORMER BREAST‐FED INFANTS AT FIVE YEARS OF AGE
Jensen, Craig L., Voigt, Robert G. , Llorente, Antolin M., Prager, Thomas C., Zou, Yi , Fraley, J. Kennard, Heird, William C., Peters, Sarika U.

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | January 3, 2024 | Volume: 39 | Issue: S1 | Pages: No page available

10.1002/j.1536-4801.2004.tb12318.x Get It

Addressing diagnostic dilemmas in eosinophilic esophagitis using esophageal epithelial eosinophil‐derived neurotoxin
Thomas, Jessina, Hopson, Puanani , Deb, Chirajyoti , Bornstein, Jeffrey D. , Mehta, Devendra I. , Bittar, Khaled, Smadi, Yamen

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | December 27, 2023 | Volume: 78 | Issue: 2 | Pages: 304-312

10.1002/jpn3.12054 | PMID 38374551 Get It

AbstractObjectivesEosinophil‐derived neurotoxin (EDN) is a viable marker of eosinophilic esophagitis (EoE) disease activity. We studied the utility of measuring EDN from esophageal epithelial brushings for diagnosing EoE, focusing on two scenarios: (1) cases of exclusive distal eosinophilia and (2) cases of discrepancy between endoscopy and histology.MethodsRecords of patients who underwent esophagogastroduodenoscopy (EGD) with EDN measured via esophageal brushings at Arnold Palmer Hospital for Children in Orlando, Florida from January 2014 to October 2018 were retrospectively reviewed. Demographics, clinical, endoscopic, and histologic data were collected.ResultsWe reviewed 231 patient records (66.7% male, mean age 10.3 years, range 1–22 years). EDN values correlated with endoscopic reference score (EREFS) and peak eosinophil count (PEC) (Spearman's rho = 0.756 (p < 0.001) and 0.824 (p < 0.001) respectively). Average PEC, EREFS, and EDN concentrations were higher in patients with active EoE than in controls or patients with EoE in remission (inactive). When grouping patients based on esophageal eosinophilia distribution, EDN mirrored PEC, and EREFS. Patients with exclusive distal eosinophilia had lower EDN concentrations than those with eosinophilia in >1 level of the esophagus (23.8 ± 46.1 mcg/mL vs. 171.3 ± 205.8 mcg/mL respectively, p < 0.001). EDN values were more consistent with EREFS in cases of discrepancies between endoscopic findings and pathology (p < 0.001).ConclusionEDN measured in esophageal brushing samples reflects disease activity objectively and accurately. It also offers significant value in cases of exclusive distal esophageal eosinophilia and when discrepancies exist between endoscopy and histology.
Capturing the Range of Disease Involvement in Localized Scleroderma: The Localized Scleroderma Total Severity Scale
Li, Suzanne C. , Rabinovich, C. Egla, Becker, Mara L. , Ferguson, Polly J. , Dedeoğlu, Fatma , Hong, Sandy , Laxer, Ronald M. , Stewart, Katie, Ibarra, Maria, Mason, Thomas G. , Higgins, Gloria C., Li, Xiaohu , Fuhlbrigge, Robert C. , Investigators, for the CARRA Registry, Dedeoglu, Fatma , Mason, Thomas, Lozy, Tara , Torok, Kathryn S. , Sivaraman, Vidya , Mason, Thomas, Pope, Elena , Investigators, for the CARRA Registry

Mayo Clinic

Arthritis Care & Research | December 27, 2023 | Volume: 76 | Issue: 5 | Pages: 616-626

10.1002/acr.25281 | PMID 38148547 Get It

ObjectiveJuvenile localized scleroderma (jLS) is a chronic autoimmune disease commonly associated with poor outcomes, including contractures, hemiatrophy, uveitis, and seizures. Despite improvements in treatment, >25% of patients with jLS have functional impairment. To improve patient evaluation, our workgroup developed the Localized scleroderma Total Severity Scale (LoTSS), an overall disease severity measure.MethodsLoTSS was developed as a weighted measure by a consensus process involving literature review, surveys, case vignettes, and multicriteria decision analysis. Feasibility was assessed in larger Childhood Arthritis and Rheumatology Research Alliance groups. Construct validity with physician assessment and inter‐rater reliability was assessed using case vignettes. Additional evaluation was performed in a prospective patient cohort initiating treatment.ResultsLoTSS severity items were organized into modules that reflect jLS disease patterns, with modules for skin, extracutaneous, and craniofacial manifestations. Construct validity of LoTSS was supported by a strong positive correlation with the Physician Global Assessment (PGA) of severity and damage and weak positive correlation with PGA‐Activity, as expected. LoTSS was responsive, with a small effect size identified. Moderate‐to‐excellent inter‐rater reliability was demonstrated. LoTSS was able to discriminate between patient subsets, with higher scores identified in those with greater disease burden and functional limitation.ConclusionWe developed a new LS measure for assessing cutaneous and extracutaneous severity and have shown it to be reliable, valid, and responsive. LoTSS is the first measure that assesses and scores all the major extracutaneous manifestations in LS. Our findings suggest LoTSS could aid assessment and management of patients and facilitate outcome evaluation in treatment studies.image
Outcomes of mechanical thrombectomy in M1 occlusion patients with or without hyperdense middle cerebral artery sign: A systematic review and meta-analysis
Orscelik, Atakan , Şenol, Yiğit Can , Bilgin, Cem , Bilgin, Gokce Belge , Pakkam, Madona , Brinjikji, Waleed , Kallmes, David F. , Arul, Santhosh , Orscelik, Atakan , Senol, Yigit Can , Bilgin, Cem , Kobeissi, Hassan , Ghozy, Sherief , Musmar, Basel , Zandpazandi, Sara

Mayo Clinic

The Neuroradiology Journal | December 26, 2023 | Volume: 37 | Issue: 4 | Pages: 454-461

10.1177/19714009231224446 | PMID 38146685 Get It

Background The comparison of mechanical thrombectomy (MT) outcomes between patients with the hyperdense middle cerebral artery sign (HMCAS) and non-HMCAS is important to evaluate the impact of this radiological finding on treatment efficacy. This meta-analysis aimed to assess the association between HMCAS and clinical outcomes in patients undergoing thrombectomy, comparing the outcomes over non-HMCAS. Methods A systematic literature search was conducted in PubMed, Ovid Embase, Google Scholar, and Cochrane Library to identify studies on MT outcomes for M1 occlusions of HMCAS over non-HMCAS. Inclusion criteria encompassed modified Rankin Scale (mRS) score, mortality, symptomatic intracranial hemorrhage (sICH), and successful recanalization. Using R software version 4.1.2, we calculated pooled odds ratios (ORs) and their corresponding 95% confidence intervals (CI). Results The meta-analysis was performed for 5 studies with 724 patients. There was no association found between presence of HMCAS and achieving mRS 0–2 (OR = 0.65, 95% CI: 0.29–1.47; p = .544). Mortality analysis also showed no significant association with presence of HMCAS (OR = 0.78, 95% CI: 0.37–1.65; p = .520). No significant difference in sICH risk (OR = 1.54, 95% CI: 0.24–9.66; p = .646) was found between groups. Recanalization analysis showed a non-significant positive association (OR = 1.23, 95% CI: 0.67–2.28; p = .501). Heterogeneity was observed in all analyses. Conclusion Our findings showed that there is no statistically significant difference in mRS scores, mortality, sICH, and recanalization success rates between the HMCAS and non-HMCAS groups.